• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    5/26/22 1:45:50 PM ET
    $APYX
    $AVDL
    $AWH
    $BIMI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APYX alert in real time by email

     

    Gainers

    • Apyx Medical (NASDAQ:APYX) shares increased by 44.6% to $5.35 during Thursday's regular session. Trading volume for Apyx Medical's stock is 19.6 million as of 13:30 EST. This is 12620.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $184.3 million.
    • Talkspace (NASDAQ:TALK) shares increased by 36.79% to $1.45. As of 13:30 EST, Talkspace's stock is trading at a volume of 6.0 million, which is 926.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $224.9 million.
    • OpGen (NASDAQ:OPGN) shares rose 25.82% to $0.47. As of 13:30 EST, this security is trading at a volume of 1.5 million shares, making up 415.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.1 million.
    • Eargo (NASDAQ:EAR) shares moved upwards by 25.66% to $1.33. As of 13:30 EST, Eargo's stock is trading at a volume of 2.9 million, which is 391.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $52.4 million. The company's, Q1 earnings came out 2 days ago.
    • Standard BioTools (NASDAQ:LAB) shares moved upwards by 25.29% to $2.1. Standard BioTools's stock is trading at a volume of 1.9 million shares as of 13:30 EST. This is 188.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $162.6 million.
    • Aspira Womens Health (NASDAQ:AWH) stock rose 24.88% to $0.53. Trading volume for Aspira Womens Health's stock is 842.7K as of 13:30 EST. This is 117.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $58.9 million.

    Losers

    • Avadel Pharmaceuticals (NASDAQ:AVDL) stock declined by 65.4% to $1.17 during Thursday's regular session. The current volume of 11.3 million shares is 1875.3% of Avadel Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $69.0 million.
    • NRX Pharmaceuticals (NASDAQ:NRXP) stock declined by 60.51% to $0.55. As of 13:30 EST, NRX Pharmaceuticals's stock is trading at a volume of 10.8 million, which is 1762.2% of its average full-day volume over the last 100 days. The company's market cap stands at $36.3 million.
    • Nurix Therapeutics (NASDAQ:NRIX) stock declined by 22.87% to $7.86. As of 13:30 EST, Nurix Therapeutics's stock is trading at a volume of 1.4 million, which is 325.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $353.3 million.
    • BIMI Intl Medical (NASDAQ:BIMI) stock decreased by 15.97% to $0.43. The current volume of 1.8 million shares is 203.0% of BIMI Intl Medical's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $4.4 million. As per the news, the Q1 earnings report came out 4 days ago.
    • Genocea Biosciences (NASDAQ:GNCA) shares decreased by 14.14% to $0.08. As of 13:30 EST, this security is trading at a volume of 26.9 million shares, making up 428.1% of its average full-day volume over the last 100 days. The company's market cap stands at $4.6 million.
    • NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock decreased by 13.9% to $0.44. Trading volume for NeuroBo Pharmaceuticals's stock is 174.9K as of 13:30 EST. This is 91.1% of its average full-day volume over the last 100 days. The company's market cap stands at $11.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APYX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APYX
    $AVDL
    $AWH
    $BIMI

    CompanyDatePrice TargetRatingAnalyst
    Nurix Therapeutics Inc.
    $NRIX
    1/8/2026$36.00Equal-Weight → Overweight
    Morgan Stanley
    Apyx Medical Corporation
    $APYX
    12/16/2025$6.00Buy
    Roth Capital
    Talkspace Inc.
    $TALK
    12/9/2025$3.50Equal Weight
    Barclays
    Nurix Therapeutics Inc.
    $NRIX
    11/24/2025$30.00Buy
    Truist
    Apyx Medical Corporation
    $APYX
    11/14/2025Mkt Perform → Mkt Outperform
    Citizens JMP
    Apyx Medical Corporation
    $APYX
    11/12/2025$8.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Talkspace Inc.
    $TALK
    10/31/2025$5.00Hold → Buy
    Needham
    Avadel Pharmaceuticals plc
    $AVDL
    10/23/2025$20.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $APYX
    $AVDL
    $AWH
    $BIMI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

    Reported record total revenue of $19.2 million in the fourth quarter of 2025Scaling U.S. commercial launch of AYON Body Contouring System™ (AYON) to meet strong market demandExpect FY2026 total revenue in the range of $57.5 million to $58.5 millionManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its fourth quarter and full year ended December 31, 2025. Recent Financial and Operating Highlights: Reported

    3/10/26 7:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Universal Health Services, Inc. to Acquire Talkspace, Inc.

    Industry-leading virtual behavioral healthcare platform accelerates outpatient strategy with expanded access to careKING OF PRUSSIA, Pa. and NEW YORK, March 9, 2026 /PRNewswire/ -- Universal Health Services, Inc. (NYSE:UHS) announced today that it has entered into a definitive agreement to acquire Talkspace, Inc. (NASDAQ:TALK) for $5.25 per share. The enterprise value for the transaction is approximately $835 million, which UHS intends to finance with borrowings pursuant to its existing revolving credit facility. Talkspace is a leading virtual behavioral healthcare company, with

    3/9/26 7:39:00 AM ET
    $TALK
    $UHS
    $UHT
    Medical/Nursing Services
    Health Care
    Hospital/Nursing Management
    Real Estate Investment Trusts

    HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD

    Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical leadership by physicians trained at Harvard, Johns Hopkins, Georgetown, and other leading Universities.Now accepting patients, call 1-833-4HOPETMS WEST PALM BEACH, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), today announced the opening of its Palm Beach, FL clinic location dedicated to the treatment of Depression and PTSD with an interventional psychiatry approach that includes ketamine1 and other neuroplastic drugs, transcranial magnetic stimulation (TMS), and hyperbaric oxygen,

    3/9/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APYX
    $AVDL
    $AWH
    $BIMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Braunstein Douglas L was granted 3,757 shares, increasing direct ownership by 0.18% to 2,083,901 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    3/3/26 9:30:08 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Director Pawar Madhu was granted 2,147 shares, increasing direct ownership by 0.56% to 388,014 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    3/3/26 9:30:11 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Director Shachar Erez was granted 2,684 shares, increasing direct ownership by 0.64% to 424,644 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    3/3/26 9:30:02 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $APYX
    $AVDL
    $AWH
    $BIMI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Talkspace Inc.

    SCHEDULE 13D/A - Talkspace, Inc. (0001803901) (Subject)

    3/10/26 5:24:53 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    SEC Form 10-K filed by Apyx Medical Corporation

    10-K - Apyx Medical Corp (0000719135) (Filer)

    3/10/26 1:11:10 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Apyx Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Apyx Medical Corp (0000719135) (Filer)

    3/10/26 7:01:32 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $APYX
    $AVDL
    $AWH
    $BIMI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Aei Capital Ltd bought $4,790 worth of shares (1,000 units at $4.79), increasing direct ownership by 0.01% to 7,646,603 units (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    7/30/25 2:04:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Chief Financial Officer Harris Ian Jiro bought $86,037 worth of shares (30,844 units at $2.79), increasing direct ownership by 5% to 615,015 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    3/5/25 4:00:06 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Cohen Jon R bought $214,500 worth of shares (75,000 units at $2.86), increasing direct ownership by 3% to 2,267,980 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    3/3/25 9:30:03 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $APYX
    $AVDL
    $AWH
    $BIMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nurix Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Nurix Therapeutics from Equal-Weight to Overweight and set a new price target of $36.00

    1/8/26 8:12:12 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Apyx Medical with a new price target

    Roth Capital initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $6.00

    12/16/25 8:46:26 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Talkspace with a new price target

    Barclays initiated coverage of Talkspace with a rating of Equal Weight and set a new price target of $3.50

    12/9/25 8:53:40 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $APYX
    $AVDL
    $AWH
    $BIMI
    Leadership Updates

    Live Leadership Updates

    View All

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

    SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology and as Chief Medical Officer and interim Chief Executive Officer of Seagen Inc., has had a distinguished career in hematology and oncology and over two decades of leadership experience in drug development and commercialization. "Roger

    11/10/25 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

    Cohen and Associates has more than a decade of leadership in interventional psychiatry and Transcranial Magnetic Stimulation (TMS) Dr. Rebecca Cohen has joined HOPE as Medical DirectorImmediate expansion is planned in Western Florida and Palm BeachAcquisition expected to be accretive to HOPE Therapeutics revenue and EBITDA MIAMI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), an interventional psychiatry network owned by NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), today announced the acquisition of a strategic interest in Cohen and Associates, LLC ("Cohen, LLC") and its incorporation into the HOPE Network. Additionally, Rebecca Cohen, MD has joined HOPE as Medical Dire

    10/20/25 8:03:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APYX
    $AVDL
    $AWH
    $BIMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 9:00:57 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 4:21:48 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 4:08:39 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APYX
    $AVDL
    $AWH
    $BIMI
    Financials

    Live finance-specific insights

    View All

    Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

    Reported record total revenue of $19.2 million in the fourth quarter of 2025Scaling U.S. commercial launch of AYON Body Contouring System™ (AYON) to meet strong market demandExpect FY2026 total revenue in the range of $57.5 million to $58.5 millionManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its fourth quarter and full year ended December 31, 2025. Recent Financial and Operating Highlights: Reported

    3/10/26 7:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Apyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025 Financial Results on March 10, 2026

    CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81

    2/25/26 9:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Talkspace Announces Fourth Quarter and Full Year 2025 Results

    4Q 2025 total revenue grew 29% year-over-year to $63.0 million4Q 2025 net income of $4.8 million and adjusted EBITDA1 of $6.6 million Full-year 2025 total revenue grew 22% year-over-year to $228.9 millionFull-year 2025 net income of $7.8 millionFull-year 2025 adjusted EBITDA1 grew 127% year-over-year to $15.8 million  NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Talkspace, Inc. ("Talkspace" or the "Company") (NASDAQ:TALK), today reported fourth quarter and full year 2025 financial results.   Three Months EndedDecember 31, Year EndedDecember 31,   2025 2024 2025 2024   Results % Variancefrom PriorYear Results % Variancefrom PriorYear (In thousands unless otherwise noted)Unaudited Unaudited  

    2/19/26 8:00:00 AM ET
    $TALK
    Medical/Nursing Services
    Health Care